UHS vs ZLAB: fair value comparison
Universal Health Services, Inc. and Zai Lab Limited · Updated 2026-10-19
ZLAB has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, UHS currently ranks higher by quality score.
| UHS | ZLAB | |
|---|---|---|
| Verdict | Undervalued | No estimate yet |
| Last price | $177.35 | $23.19 |
| 12-month range | $141.17–$244.18 | $16.30–$28.02 |
| Rank by discount to fair value | #22 of 108 Healthcare | — |
| Rank by quality score | #124 of 301 Healthcare | #125 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Moderate | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Undervalued | — |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: UHS fair value analysis · ZLAB fair value analysis